Kabra Drugs Ltd vs Sun Pharmaceutical Industries Ltd

A side-by-side comparison of Kabra Drugs Ltd (KABRADG) and Sun Pharmaceutical Industries Ltd (SUNPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Sun Pharmaceutical Industries Ltd leads KABRADG vs SUNPHARMA on 9 of 14 metrics (2 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

10.30
P/E ratio
41.01
1.73
P/B ratio
5.60
0.00%
Dividend yield
0.82%
₹2.07
EPS
₹47.84

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

-4.40%
Return on equity
16.00%
-7.82%
Return on capital
21.00%
0.00%
EBITDA margin
30.00%
0.00%
Net margin
19.69%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

Revenue CAGR (3Y)
10.03%
Profit CAGR (3Y)
10.57%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹51 Cr
Market cap
₹4.67L Cr
₹0 Cr
Revenue
₹58,462 Cr
₹-1 Cr
Net profit
₹11,509 Cr
0.02
Debt / equity
0.06
Kabra Drugs Ltd
  • + ["Company is almost debt free."]
  • ["Company has a low return on equity of 7.79% over last 3 years.", "Company has high debtors of 279 days."]
Sun Pharmaceutical Industries Ltd
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 34.1%"]
  • ["The company has delivered a poor sales growth of 11.8% over past five years."]
Kabra Drugs Ltd full analysis Sun Pharmaceutical Industries Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.